Trek Therapeutics PBC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.trektx.com
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
Phase 2
Completed
- Conditions
- Chronic Hepatitis CHepatitis C (HCV)Hepatitis C Genotype 1Hepatitis C Viral Infection
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- Trek Therapeutics, PBC
- Target Recruit Count
- 25
- Registration Number
- NCT02716428
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸Bach and Godofsky Infectious Diseases, Bradenton, Florida, United States
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
Phase 2
Completed
- Conditions
- Hepatitis C Viral InfectionChronic Hepatitis CHepatitis C Genotype 4Hepatitis C (HCV)
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Trek Therapeutics, PBC
- Target Recruit Count
- 16
- Registration Number
- NCT02593162
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
© Copyright 2025. All Rights Reserved by MedPath